Acute Decompensated Cardiac Failure



Heart failure (HF) is a serious condition affecting an estimated 2 million Americans and is a common reason for hospitalization. Acute decompensated heart failure (ADHF) refers broadly to new or worsening of signs and symptoms of HF that are progressing rapidly, whereby unscheduled medical care or hospital evaluation is necessary. The ADHERE registry is a national registry (in the United States) designed to study the characteristics, the management, and outcomes of patients (over 200,000) hospitalized with ADHF.1 A preliminary analysis of this registry reported the mean age to be 72 years with 52% of the patients being women. The most common comorbid conditions were hypertension (73%), coronary artery disease (57%), and diabetes (44%). Evidence of mild or no impairment of systolic function was found in 46% of patients. In-hospital mortality was 4.0% and the median hospital length of stay was 4.3 days.


Heart Failure Left Ventricular Systolic Dysfunction Acute Decompensated Heart Failure Systolic Heart Failure Diastolic Heart Failure 


  1. 1.
    Adams KF Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216.PubMedCrossRefGoogle Scholar
  2. 2.
    Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(Suppl 7):S21–S30.PubMedGoogle Scholar
  3. 3.
    Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21:669–674.PubMedCrossRefGoogle Scholar
  4. 4.
    Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988;77:607–612.PubMedCrossRefGoogle Scholar
  5. 5.
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328.PubMedCrossRefGoogle Scholar
  6. 6.
    Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843–849.PubMedCrossRefGoogle Scholar
  7. 7.
    Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167.PubMedCrossRefGoogle Scholar
  8. 8.
    Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283.PubMedCrossRefGoogle Scholar
  9. 9.
    Cavallazzi R, Nair A, Vasu T, et al. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med. 2008;34:2147–2156.PubMedCrossRefGoogle Scholar
  10. 10.
    Levitt JE, Vinayak AG, Gehlbach BK, et al. Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. Crit Care. 2008;12:R3.PubMedCrossRefGoogle Scholar
  11. 11.
    Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980–988.PubMedCrossRefGoogle Scholar
  12. 12.
    Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818–827.PubMedCrossRefGoogle Scholar
  13. 13.
    Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–1633.PubMedCrossRefGoogle Scholar
  14. 14.
    Winck JC, Azevedo LF, Costa-Pereira A, et al. Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema – a systematic review and meta-analysis. Crit Care. 2006;10:R69.PubMedCrossRefGoogle Scholar
  15. 15.
    Ho KM, Wong K. A comparison of continuous and bi-level positive airway pressure non-invasive ventilation in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Crit Care. 2006;10:R49.PubMedCrossRefGoogle Scholar
  16. 16.
    Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25:205–209.PubMedCrossRefGoogle Scholar
  17. 17.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112:e154–e235.Google Scholar
  18. 18.
    Stampfer M, Epstein SE, Beiser GD, et al. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation. 1968;37:900–911.PubMedCrossRefGoogle Scholar
  19. 19.
    Emerman CL, Marco TD, Costanzo MR, et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Card Fail. 2009;10:S116.CrossRefGoogle Scholar
  20. 20.
    Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393.PubMedCrossRefGoogle Scholar
  21. 21.
    Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188–195.PubMedCrossRefGoogle Scholar
  22. 22.
    den Uil CA, Caliskan K, Lagrand WK, et al. Dose-dependent benefits of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Med. 2009;35:1893–1899.Google Scholar
  23. 23.
    Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905.PubMedCrossRefGoogle Scholar
  24. 24.
    Leier CV. Positive inotropic therapy: an update and new agents. Curr Probl Cardiol. 1996;21:521–581.PubMedCrossRefGoogle Scholar
  25. 25.
    Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997–1003.PubMedCrossRefGoogle Scholar
  26. 26.
    Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98–104.PubMedCrossRefGoogle Scholar
  27. 27.
    Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079–1082.PubMedCrossRefGoogle Scholar
  28. 28.
    Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–2677.PubMedCrossRefGoogle Scholar
  29. 29.
    Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–1780.PubMedCrossRefGoogle Scholar
  30. 30.
    Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:e9-1096–e15-1096.CrossRefGoogle Scholar
  31. 31.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293–302.Google Scholar
  32. 32.
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355.PubMedCrossRefGoogle Scholar
  33. 33.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.Google Scholar
  34. 34.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.PubMedCrossRefGoogle Scholar
  35. 35.
    The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525–533.Google Scholar
  36. 36.
    O’Connor CM, Carson PE, Miller AB, et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82:881–887.PubMedCrossRefGoogle Scholar
  37. 37.
    Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–1940.PubMedCrossRefGoogle Scholar
  38. 38.
    An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673–682.Google Scholar
  39. 39.
    Rossi A, Rossi G, Piacenti M, et al. The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients: a meta-analysis from clinical trials. Heart Vessels. 2008;23:217–223.PubMedCrossRefGoogle Scholar
  40. 40.
    Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.PubMedCrossRefGoogle Scholar
  41. 41.
    Kale P, Fang JC. Devices in acute heart failure. Crit Care Med. 2008;36:S121–S128.PubMedCrossRefGoogle Scholar
  42. 42.
    Schreuder JJ, Maisano F, Donelli A, et al. Beat-to-beat effects of intraaortic balloon pump timing on left ventricular performance in patients with low ejection fraction. Ann Thorac Surg. 2005;79:872–880.PubMedCrossRefGoogle Scholar
  43. 43.
    Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152:469–468.Google Scholar
  44. 44.
    Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959.PubMedCrossRefGoogle Scholar
  45. 45.
    Lam CS, Roger VL, Rodeheffer RJ. Cardiac structure and ventricular–vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982–1990.PubMedCrossRefGoogle Scholar
  46. 46.
    Tribouilloy C, Rusinaru D, Mahjoub H. Prognosis of heart failure with preserved ejection fraction: a 5-year prospective population-based study. Eur Heart J. 2008;29:339–347.PubMedCrossRefGoogle Scholar
  47. 47.
    Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184–192.PubMedCrossRefGoogle Scholar
  48. 48.
    Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care MedicineEastern Virginia Medical SchoolNorfolkUSA

Personalised recommendations